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Prostanoidit muodostuvat solukalvojen rasvahapoista syklo-oksygenaasientsyymien (COX-1 ja 
COX-2) katalysoimana. Prostaglandiini E2 (PGE2) on fysiologisten tehtäviensä lisäksi tärkeä 
tulehduksen ja tulehduskivun välittäjäaine. mPGES-1 on PGE2:n muodostumista katalysoiva 
entsyymi, jonka ilmentyminen lisääntyy tulehdusreaktion yhteydessä. 
 
Nykyisten tulehduskipulääkkeiden teho perustuu COX-entsyymien toiminnan estoon. Tämän 
seurauksena PGE2:n  lisäksi muidenkin prostanoidityyppien ilmentyminen vähenee, mistä aiheutuu 
COX-estäjille tyypillisiä haittavaikutuksia. On esitetty, että yhdisteillä, jotka selektiivisesti 
estäisivät mPGES-1:n aktiivisuutta tai ilmentymistä, olisi tulehduskipulääkkeiden kaltainen teho, 
mutta vähemmän haittavaikutuksia.  
 
Tutkimuksen tavoitteena oli pystyttää malli, jossa voidaan tutkia mPGES-1:n ilmentymistä ihmisen 
rustosoluissa ja edelleen mitata markkinoilla olevien reumalääkkeiden vaikutuksia mPGES-1:n 
ilmentymiseen. 
 
Rustokudosnäytteet saatiin tekonivelleikkauspotilailta. mPGES-1:n ilmentymistä tutkittiin käyttäen 
RT-PCR  ja Western Blot-menetelmiä. Näytteiden PGE2-pitoisuudet määritettiin käyttäen ELISA-
menetelmää. 
 
Viljellyt rustosolut ilmensivät mPGES-1-entsyymiä. Kun viljelmään lisättiin IL-1β:aa, mPGES-1:n 
ilmeneminen lisääntyi voimakkaasti. mRNA:n ilmentyminen lisääntyi 48 tunnin ajan, minkä 
jälkeen se alkoi vähentyä. Proteiinin ilmentyminen lisääntyi koko 96 tunnin seurannan ajan. 
 
Tässä tutkimuksessa havaittiin että aurotiomalaatti vähensi mPGES-1:n ilmentymistä selvästi, kun 
taas muut tutkitut  reumalääkkeet (metotreksaatti, sulfasalatsiini, hydroksiklorokiini) eivät 
vaikuttaneet mPGES-1:n ilmentymiseen rustosoluissa. Aurotiomalaatin vaikutus mPGES-1:n 
ilmentymiseen kliinisesti merkittävällä pitoisuudella (25 µM) oli verrattavissa deksametasoniin, 
jonka tiedetään vähentävän mPGES-1:n ilmentymistä useissa solutyypeissä. Aurotiomalaatti 
vähensi myös PGE2:n pitoisuutta soluissa deksametasonin tavoin. 
 
Löydöksen perusteella voidaan esittää uusi tulehdusreaktiota vaimentava mekanismi 
aurotiomalaatille. Tutkimuksen tuloksia voidaan hyödyntää jatkossa tutkittaessa mPGES-1:n 
ilmentymisen säätelyyn vaikuttavia tekijöitä ja kehitettäessä uusia anti-inflammatorisia lääkkeitä. 
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 4 
INTRODUCTION 
 
Prostaglandins are essential regulator molecules synthesized from arachidonic acid originating from 
cellular membranes. Arachidonic acid is metabolized to prostaglandin G2 (PGG2) and onwards to 
prostaglandin H2 (PGH2) by the constitutive cyclooxygenase 1 (COX-1) and by the inducible 
cyclooxygenase 2 (COX-2) enzyme which is up-regulated especially during inflammation (Figure 
1). 
 
Prostaglandin E2 (PGE2) is formed from PGH2 by enzymes known as PGE synthases. Microsomal 
prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme expressed in various human cell 
types (1) whereas the two other PGE2 synthases, microsomal prostaglandin E synthase-2 (mPGES-2) 
and cytosolic prostaglandin E synthase (cPGES), are constitutively expressed and presumed to have 
a physiological role. mPGES-1, as well as COX-2 enzyme, is induced by inflammatory cytokines 
such as interleukin-1β (IL-1β), lipopolysaccharide (LPS) and tumour necrosis factor-α (TNF-α) 
(2,3). COX-2 and mPGES-1 are both overexpressed in connection with pathological processes 
including inflammation. 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both of the COX enzymes suppressing the 
formation of PGH2 and all of its terminal products including PGE2. Inhibition of PGE2 synthesis is 
regarded as the main mechanism of the therapeutic effects of NSAIDS. Unfortunately, the most 
common adverse effects of NSAIDs also appear to be mediated through reduced prostanoid 
production. Especially the cardiovascular side effects now known to be associated with the use of 
both non-selective and COX-2 selective NSAIDs are mediated through inhibition of the synthesis of 
prostanoids other than PGE2 (3-5). A specific mPGES-1 inhibitor is therefore hypothesized to retain 
the therapeutic activity of NSAIDs with less adverse effects (5,6). 
 
In addition to its physiological roles, PGE2 is a vital mediator of inflammatory responses, pain and 
fever playing an important role in the mechanisms and symptoms of rheumatic diseases. mPGES-1 
levels have previously been shown to be high in the synovial cells from patients with rheumatoid 
arthritis (RA)  (7)  and osteoarthritis (OA) (8). A convincing evidence of its pathophysiological role 
is also presented in an experimental model of RA in mPGES-1 knockout mice where the incidence 
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and severity of the disease, its clinical score and joint damage were reduced in knockout mice as 
compared to wild type controls (9). This suggests that inhibition of the pathological increase of 
mPGES-1 levels during arthritis might suppress the inflammatory activity and prevent / retard the 
progression of joint erosions. 
 
The aim of the present study was to investigate the expression of mPGES-1 in activated primary 
human chondrocytes, and to study the effects of DMARDs methotrexate, sulfasalazine 
aurothiomalate and hydroxychloroquine, and of glucocorticoid dexamethasone on it. 
 
MATERIALS AND METHODS 
 
The study was approved by the Ethics Committee of Tampere University Hospital, Tampere, 
Finland and a written informed consent was obtained from the patients. Leftover pieces of OA 
cartilage from knee joint replacement surgery were received from Coxa Hospital for Joint 
Replacement, Tampere, Finland and processed as earlier described (10). 
 
Isolated chondrocytes were plated at the density of 0.15 milj/ml in 24-well plates in DMEM culture 
medium with GIBCO GlutaMAX-I supplemented with penicillin (100 U/ml), streptomycin (100 
µg/ml) and amphotericin B (250 ng/ml) containing 10% fetal bovine serum, and cultured at 37°C in 
a humidified 5% carbon dioxide atmosphere. After 24h incubation, the cells were treated with the 
compounds of interest. RNA or proteins were extracted and cell culture media collected after the 
desired time of incubation. RNA extraction and real-time RT-PCR, preparation of cell lysates for 
Western blot, and Western blot analysis were carried out as previously described (11). 
 
Primer and probe sequences for human mPGES-1 were CACGCTGCTGGTCATCAAGA (forward), 
CCGTGTCTCAGGGCATCCT (reverse) and AGCCTCACTTGGCCCGTGATG (probe). 
Antibodies used in Western blot analysis were rabbit polyclonal antibody for mPGES-1 (AS-03031, 
Agrisera AB, Vännäs, Sweden; primary antibody) and goat anti-rabbit IgG-HRP (sc-2004, Santa 
Cruz, CA, USA; secondary antibody). Concentrations of PGE2 in the cell culture medium samples 
were determined by ELISA (Cayman Chemical Co, MI, USA). 
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Cell culture medium and its supplements were from Invitrogen/Life Technologies (CA, USA), IL-
1ß was purchased from R&D Systems Inc (MA, USA), dexamethasone, methotrexate and 
hydroxychloroquine were from Orion Corp. (Espoo, Finland), and all other reagents were obtained 
from Sigma Chemical Co. (MO, USA). 
 
The results were analyzed with one-way ANOVA followed by Dunnett’s post test by using InStat 
version 3.05 for Windows. Results are expressed as mean + standard error of the mean (SEM). P 
value lower than 0.05 was considered to indicate statistical significance. 
 
RESULTS 
 
mPGES-1 expression in unstimulated chondrocytes was low and a clear increase in its expression 
levels were found when IL-1β was introduced into the culture (Fig. 2). mPGES-1 mRNA 
expression increased up to 48 h and declined thereafter (Fig. 2A) whereas the protein expression 
continued to increase throughout the 96 h follow-up (Fig. 2B). As seen in Figure 2, the mPGES-1 
expression in IL-1β –activated primary chondrocytes demonstrated relatively slow onset and long 
duration. 
 
The effects of dexamethasone, aurothiomalate, sulfasalazine, methotrexate and hydroxychloroquine 
on IL-1ß –induced mPGES-1 expression were investigated. Aurothiomalate and dexamethasone 
significantly down-regulated mPGES-1 expression whereas sulfasalazine, methotrexate and 
hydroxychloroquine had no effect (Fig 3A). The effect of aurothiomalate on mPGES-1 mRNA 
expression was dose-dependent (Fig. 3B) and it was reflected as reduced mPGES-1 protein levels 
(Fig. 3C) and PGE2 production (Fig. 3D).  
 
DISCUSSION 
 
In the present study, we measured the expression of mPGES-1 in primary human chondrocytes, and 
investigated the effects of DMARDs aurothiomalate, sulfasalazine, methotrexate and 
hydroxychloroquine, and dexamethasone on it. Interestingly, aurothiomalate was found to inhibit 
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the expression of mPGES-1 which is an original finding. The other DMARDs studied did not effect 
mPGES-1 expression while dexamethasone reduced mPGES-1 levels and PGE2 production. The 
effects of aurothiomalate on mPGES-1 expression and PGE2 production were dose-dependent, and 
a significant inhibition was achieved at clinically relevant concentration of 25 µM which can be 
maintained in serum during intramuscular aurothiomalate treatment (12). Further, aurothiomalate 
levels in synovial fluid are reported to correspond the serum levels during drug treatment (13). 
 
It has previously been reported that glucocorticoids inhibit the expression of both mPGES-1 and 
COX-2 enzymes (2) and therefore dexamethasone was selected as a control compound when we 
evaluated the effects of disease-modifying antirheumatic drugs (DMARD) on the expression of 
mPGES-1. Methotrexate, sulfasalazine and hydroxychloroquine (triple therapy) were selected to 
this design because using them with a small dose of glucocorticoid as a combination therapy is 
evidently more effective treatment in RA than using a single DMARD with or without a small daily 
dose of glucocorticoid (14). The above mentioned combination is also recommended in the 
“Current Care Guidelines” in Finland as a primary treatment of an early active RA. TNF-alpha 
blockers which are nowadays widely used in the treatment of RA not responding adequately to 
traditional DMARDs, have been shown not to have an effect on mPGES-1 expression in synovial 
tissue (15) and therefore they were not included in this study. 
 
Aurothiomalate is a traditional antirheumatic drug used in the treatment of RA since early 1930s 
(16). It is known to be an effective treatment for RA but its clinical usability is limited because of 
adverse effects. The molecular mechanisms of the anti-inflammatory and antirheumatic action of 
aurothiomalate are not known in detail. Aurothiomalate was reported to inhibit prostaglandin 
synthesis already in 1974 (17) and it was found to down-regulate the expression of COX-2 in 
murine chondrocytes by destabilizing its mRNA (18). Also, aurothiomalate was recently reported to 
enhance the expression of mitogen activated protein kinase phosphatase 1 (MKP-1) in murine and 
human chondrocytes (19) which can be linked to down-regulation of inflammatory genes. Findings 
in the present study introduce mPGES-1 as a novel target of aurothiomalate and extend our 
knowledge on the mechanisms of action of this DMARD. 
 
The key role of mPGES-1 in pain and inflammatory responses has been convincingly demonstrated 
in experiments with mPGES-1 deficient mice. The knockout mice seem to develop normally but 
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they have attenuated inflammatory and pain responses, also in models of arthritis. Nephrotoxicity, 
skin reactions and gastrointestinal complications, side-effects of aurothiomalate treatment, have not 
been reported in mPGES-1 knockout mice (9) indicating that those adverse effects are most likely 
not mediated by down-regulation of mPGES-1. 
 
PGE2 is also an essential mediator of inflammatory pain. It has recently been found to induce and 
amplify pain perception by activating peripheral nociceptors via specific PGE2-receptors, and also 
to modulate the activity of pain pathways in the spinal cord (20). The connection between different 
forms of pain and different PGE2-receptor subtypes are currently under intensive research.  
 
A selective inhibition of PGE2 formation might be an effective manner to treat many types of pain 
with less adverse effects as compared to NSAIDs. Intensive research on mPGES-1 inhibitors has 
been ongoing since the enzyme was characterized, and many compounds with different molecular 
structures seem to inhibit it, but a specific inhibitor appliable for clinical use is yet to be discovered 
(5,21-24). Another approach to reduce PGE2 production especially in inflammatory conditions 
might be down-regulation of mPGES-1 expression and according to the present findings that is 
achieved by using aurothiomalate but not with the other commonly used DMARDs. 
 
In conclusion, the results of the present study introduce aurothiomalate as the first and so far the 
only DMARD found to be able to inhibit mPGES-1 expression. The effect is likely involved in the 
mechanisms of action for this gold containing DMARD in rheumatic diseases. These results are 
implicated in the regulatory mechanisms of mPGES-1 that are under intensive research to develop 
improved treatments for inflammation and inflammatory pain.  
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FIGURE LEGENDS 
 
Figure 1: Biosynthesis of prostaglandin E2 and other prostanoids from arachidonic acid originated 
from cellular membranes. COX, cyclooxygenase; PGG2, prostaglandin G2; PGH2, prostaglandin H2; 
mPGES-1/2, microsomal prostaglandin E synthase 1/2; cPGES, cytosolic prostaglandin E synthase; 
PGE2, prostaglandin E2; PGD2, prostaglandin D2; PGF2α, prostaglandin F2α; PGI2, prostaglandin I2; 
TXA2, thromboxane A2. 
 
Figure 2: The time-dependent expression of mPGES-1 enzyme in primary human chondrocytes in 
response to IL-1β. 
A: Cells were incubated with IL-1β (100 pg/ml) and RNA was extracted at indicated time-points. 
mPGES-1 mRNA levels were analyzed with quantitative real-time reverse transcription–
polymerase chain reaction (RT-PCR) and normalized against GAPDH. Untreated cells were used as 
control, and expression levels were quantified against them.  
B: Cells were incubated with IL-1β (100 pg/ml) and proteins were extracted at indicated time-points. 
Untreated cells were used as control, and mPGES-1 expression levels determined by Western 
blotting were quantified against them. Actin was used as a loading control.  
Values are mean + SEM expressed as fold increase from baseline (considered as 1) in arbitrary 
units, n=4-6, ** = p < 0.01. 
 
Figure 3: The effects of dexamethasone and DMARDs on the expression of mPGES-1 and 
production of PGE2 in primary human chondrocytes. The IL-1β-treated cells were considered as 
100 % and the expression levels were quantified as percentages of them. 
A and B: Cells were treated with IL-1β (100 pg/ml) and the compounds of interest for 48 h and 
RNA was extracted thereafter, subjected to RT-PCR and normalized against GAPDH. Untreated 
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cells were used as control, and expression levels were quantified against IL-1β –treated cells. 
Values are mean + SEM, n=4-11, ** = p < 0.01. 
C: Cells were incubated with IL-1β (100 pg/ml) and the compounds of interest for 72 h, and 
proteins were extracted thereafter. Untreated cells were used as control, and mPGES-1 expression 
levels determined by Western blotting were quantified against IL-1β –treated cells. Actin was used 
as a loading control. Values are mean + SEM, n=8, ** = p < 0.01. 
D: Cells were incubated with IL-1β (100 pg/ml) and the compounds of interest for 48 h, and cell 
culture medium was collected thereafter. Untreated cells were used as control, and PGE2 levels 
determined by ELISA were quantified against IL-1β –treated cells. Values are mean + SEM, n = 3-
4, ** = p < 0.01. 
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